Compare Charles River Laboratories Intl. Inc (CRL) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Innodata Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $287.02 (market cap $13.46B), while Innodata Inc trades at $61.94 (market cap $2.05B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 6.6× Innodata Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.
| CRL | INOD | |
|---|---|---|
Market Cap | $13.46B | $2.05B |
Sector | Health | Technology |
52-Week High | $282.00 | $121.50 |
52-Week Low | $145.57 | $34.45 |
Enterprise Value | $16.30B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
INOD trades at $62.26, up 0.06% on the day, with a bullish technical signal supported by oscillators and strong momentum indicators. The company reported robust Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and margin expansion. Analyst consensus is bullish with a $130 price target, reflecting optimism around AI-driven growth and profitability improvements.
Outlook remains positive due to accelerating AI demand and operational leverage, though the stock's premium valuation (P/E 48.62) poses a risk if growth moderates. Key opportunities include continued AI adoption and customer diversification, while risks involve execution challenges and competitive pressures in the AI services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
